<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39288794</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1741-2552</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>17</Day></PubDate></JournalIssue><Title>Journal of neural engineering</Title><ISOAbbreviation>J Neural Eng</ISOAbbreviation></Journal><ArticleTitle>Building consensus on clinical outcome assessments for BCI devices. A summary of the 10th BCI society meeting 2023 workshop.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1088/1741-2552/ad7bec</ELocationID><Abstract><AbstractText>The 10th International Brain Computer Interface (BCI) Society Meeting, 'Balancing Innovation and Translation', was held from the 6th to 9th of June 2023 in Brussels, Belgium. This report provides a summary of the workshop 'Building Consensus on Clinical Outcome Assessments (COAs) for BCI Devices'. This workshop was intended to give participants an overview of the current state of BCI, future opportunities, and how different countries and regions provide regulatory oversight to support the BCI community to develop safe and effective devices for patients. Five presentations and a panel discussion including representatives from regulators, industry, and clinical research stakeholders focused on how various stakeholders and the BCI community might best work together to ensure studies provide data that is useful for evaluating safety and effectiveness, including reaching consensus on clinical outcome assessments (COAs) that represent clinically meaningful benefits and support regulatory and payor requirements. This report focuses on the regulatory and reimbursement requirements for medical devices and how to best measure safety and effectiveness and summarizes the presentations from five experts and the discussion between the panel and the audience. Consensus was reached on the following items specifically related to BCI: (i) the importance of and need for a new generation of COAs, (ii) the challenges facing the development of appropriate clinical outcome assessments, and (iii) that improvements in COAs should demonstrate obvious and clinically meaningful benefit(s). There was discussion on: (i) clinical trial design for BCIs and (ii) considerations for payor reimbursement and other funding. Whilst the importance of building community consensus on COAs was apparent, further collaboration will be required to reach consensus on which specific current and/or novel COAs could be used for the BCI field to evolve from research to market.</AbstractText><CopyrightInformation>© 2024 IOP Publishing Ltd. All rights, including for text and data mining, AI training, and similar technologies, are reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sawyer</LastName><ForeName>Abbey</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5153-5927</Identifier><AffiliationInfo><Affiliation>Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai, 5E 98th St, The Mount Sinai Hospital, New York, New York, 10029, UNITED STATES.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chetty</LastName><ForeName>Nikole</ForeName><Initials>N</Initials><Identifier Source="ORCID">0009-0002-9069-4028</Identifier><AffiliationInfo><Affiliation>Mechanical Engineering, Carnegie Mellon University, 5000 Forbes Avenue, Pittsburgh, Pennsylvania, 15213-3815, UNITED STATES.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMullen</LastName><ForeName>David P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Food and Drug Administration, Food and Drug Administration, Washington, District of Columbia, 20001, UNITED STATES.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dean</LastName><ForeName>Heather</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Food and Drug Administration, Food and Drug Administration, Washington, District of Columbia, 20001, UNITED STATES.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eisler</LastName><ForeName>Jacek</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>TÜV SÜD, Westendstraße 199. D-80686, Munich, D-80686, GERMANY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fried-Oken</LastName><ForeName>Melanie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Child Development &amp; Rehabilitation Center, Oregon Health and Science University, P. O. Box 574, Portland, Oregon, Portland, Oregon, 97207, UNITED STATES.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hochberg</LastName><ForeName>Leigh R</ForeName><Initials>LR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, 55 Fruit Street, Boston, Massachusetts, 02114, UNITED STATES.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gibbons</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Smartbox, 2831 Leechburg Road, New Kensington, Pennsylvania, 15068, UNITED STATES.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waite</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Blackrock Neurotech, 630 Komas Drive, Suite 200, Salt Lake City, Utah, 84108-1262, UNITED STATES.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oxley</LastName><ForeName>Tom</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-5569-3612</Identifier><AffiliationInfo><Affiliation>Synchron Inc, Brooklyn, Brooklyn, New York, 11205, UNITED STATES.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fry</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Synchron Inc, Brooklyn, Brooklyn, New York, 11205, UNITED STATES.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weber</LastName><ForeName>Douglas J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Carnegie Mellon University, 1323 Wean Hall, Pittsburgh, Pennsylvania, 15213-3815, UNITED STATES.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Putrino</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, 5E 98th Street, New York, New York, 10029-6574, UNITED STATES.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neural Eng</MedlineTA><NlmUniqueID>101217933</NlmUniqueID><ISSNLinking>1741-2552</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Assessments</Keyword><Keyword MajorTopicYN="N">BCI</Keyword><Keyword MajorTopicYN="N">Brain computer interface</Keyword><Keyword MajorTopicYN="N">Clinical</Keyword><Keyword MajorTopicYN="N">Outcomes</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>18</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>18</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>17</Day><Hour>19</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39288794</ArticleId><ArticleId IdType="doi">10.1088/1741-2552/ad7bec</ArticleId></ArticleIdList></PubmedData></PubmedArticle>